Kenneth Carlson Email & Phone Number

Boston, MA, US

Boston, Massachusetts, United States

Greater Boston Area

• Cyclerion was spun-off from Ironwood Pharmaceutics in April 2019
• Program Leader of multi-disciplinary team responsible for identifying a lung-targeted aerosolized small molecule stimulator of soluble guanylate cyclase for treatment of rare pulmonary diseases; advanced lead molecule.
• Led effort with commercial and clinical research teams to identify pulmonary disease opportunities and to develop clinical/translational strategy

Greater Boston Area

• Program Leader of discovery phase pulmonary inflammation/fibrosis small molecule program
• Drove the development of inhalation dosing capabilities and expertise at Ironwood
• Co-leader of company-wide Translational Science Team, responsible for identifying biomarker panels for ongoing clinical studies and for executing on biomarker strategy
• Co-led cross-company effort to characterize the company’s primary drug target, soluble guanylate cyclase; responsible for driving mechanistic studies, genetic validation, and interactions with academic collaborators
• Led FTE-intensive, collaborative program with Protagonist Therapeutics in the identification of peptide-based cytokine therapeutics for auto-immune indications
• Leader of Peptide Therapeutic Team, responsible for identifying novel, peptide-based therapeutic targets and opportunities

Greater Boston Area

• Head of Biology; successfully built a high functioning team with expertise in in vitro pharmacology, in vivo pharmacology, and mechanistic biology
• Member of Executive Management Team that set strategy and tactics for the company and interfaced with the Board of Directors and Scientific Advisory Board
• Facilitated creation of the strategic direction and vision of the company - positioned Anchor as a cutting edge GPCR company focused on the development of allosteric modulators and biased ligands
• Made numerous presentations at scientific conferences, business development events and Board meetings. Led the company to its first scientific publication and authored several high impact papers. Established research.
• Oversaw multiple drug discovery programs including projects in diabetes, inflammation, stem cell recruitment, and cardiovascular disease. Led several successful projects within J&J alliance, including an oncology.

Cranbury, New Jersey

• Member of Executive Management Team
• Executive Director of Biology Department; built high functioning group responsible for conducting in vitro and in vivo studies and development of models for obesity, diabetes, heart failure and sexual dysfunction
• Led successful effort to engineer out known side effect profiles (sexual response and hemodynamic) from melanocortin agonist drug candidates for obesity
• Co-chaired alliance program with Astra-Zeneca resulting in the successful identification of AZD2820, a peptide-based melanocortin receptor agonist, which entered into Clinical Trials for the treatment of obesity
• Drove pharmacology, safety and biomarker studies to support development of PL-3994, a natriuretic peptide receptor A (NPRA) agonist in clinical trials for refractory hypertension

Princeton, New Jersey

• BRISTOL-MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTESenior Principal Scientist, Metabolic and Cardiovascular Drug Discovery (2005 – June 2007)Principal Scientist, Metabolic and Cardiovascular Drug Discovery (2003.
• Chaired a multi-disciplinary discovery team of 40+ members that successfully identified and advanced a Cannabinoid-1 Receptor small molecule clinical candidate. Member of the Development team that advanced the.
• Led an Institute-wide GPCR Target Team that was rewarded with a prestigious Triumph Award for its many successes, including establishment and implementation of strategies for orphan receptor drug discovery, focused.
• Led a team that successfully identified a potent, selective and in vivo active agonist for the melanocortin-1 receptor for vascular inflammation; published a seminal paper on this effort
• In vitro pharmacology leader of a Dual Endothelin/Angiotensin II Receptor Program that successful progressed a candidate into the clinic for hypertension and heart failure
• Led multiple early phase programs focused on developing small molecule antagonists of chemokine receptors

Doctor Of Philosophy - Phd, Pharmacology

Ph.D. Advisor: Dr. Dave Manning Dissertation: Post-translational regulation of guanine nucleotide-binding proteins

Post-Doctoral Training, Prat Fellow, Cancer Research

Mentor: Dr. Gordon Hager Research Focus: Transcriptional control of the mouse mammary tumor virus Long Terminal Repeat

Master Of Arts - Ma, Neurobiology

Accelerated Combined B.A./M.A. Program Advisor: Dr. Chris Price Dissertation: Retrograde axonal transport of free glycine in identified.

Bachelor Of Arts - Ba, Biology, Magna Cum Laude With Distinction

Accelerated Combined B.A./M.A. Program Advisor: Dr. Christopher Price Thesis: Retrograde axonal transport of free glycine in the branchial.